I did not perform Fragmentation for my 1st FFPE sample. Now I am thinking I may need do to do that to narrow the insert size ...
Unconfigured Ad
Collapse
X
-
RNA size range as yours - but with a sligthly higher peak ~200 nt. How do you purify the library after amplification? Using MiniElute will give you some "primer-dimer" contamination. We are using AMPure XP but you may need to play around with the bead ratio to get rid of the "primer-dimer" without removing too much of the library. Have you considered gel purification?Originally posted by HedleyC View PostJakob, I have been involved in a piece of work trying to do the same thing - but we just got massive adapter contamination in the final data. What size range was your FFPE RNA peak after RiboZero GOLD but before the ScriptSeq? Ours was between 25-500bp approximately, peak generally around 100.
Regards,
Hedley
/Jakob
Comment
-
Hi Jakob,Originally posted by JakobHedegaard View PostRNA size range as yours - but with a sligthly higher peak ~200 nt. How do you purify the library after amplification? Using MiniElute will give you some "primer-dimer" contamination. We are using AMPure XP but you may need to play around with the bead ratio to get rid of the "primer-dimer" without removing too much of the library. Have you considered gel purification?
/Jakob
The ScriptSeq and later steps were performed by a 3rd party. They used AMPure XP, but it's unclear if they used the right bead ratio to minimise carry-through of the adapter dimers (I suspect not). We are doing some repeat work and also looking at another FFPE kit, so if I find out anything useful, will post it here at some point.
/Hedley
Comment
-
@ServiceXS, we obtained enough (>500 ng total RNA) purifiying from 2-3 sections from a FPFE block. For Ribo-Zero we started with 500 ng total RNA but have prepared libraries with 100 ng RNA - but with more variation in quality and yield.
@woodydon, using Ribo-Zero will result in a much more complex library than using poly-dA selected RNA. Depending on the sample conditions (tissue, stage, etc.) some transcripts can dominate the profile - and this applies to both poly-dA and Ribo-Zero treated RNA. Analysing data from Ribo-Zero treated RNA, I think the major challenge is the profiling of both mature and pre-spliced transcripts which introduce some kind of bias.
Cheers, /Jakob
Comment
-
@ServiceXS, we obtained enough (>500 ng total RNA) purifiying from 2-3 sections from a FPFE block. For Ribo-Zero we started with 500 ng total RNA but have prepared libraries with 100 ng RNA - but with more variation in quality and yield.
@woodydon, using Ribo-Zero will result in a much more complex library than using poly-dA selected RNA. Depending on the sample conditions (tissue, stage, etc.) some transcripts can dominate the profile - and this applies to both poly-dA and Ribo-Zero treated RNA. Analysing data from Ribo-Zero treated RNA, I think the major challenge is the profiling of both mature and pre-spliced transcripts which introduce some kind of bias.
Cheers, /Jakob
Comment
Latest Articles
Collapse
-
by SEQadmin2
CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).
Despite this, “CRISPR helped turn genome editing from a specialized technique into...-
Channel: Articles
07-31-2026, 11:01 AM -
-
by SEQadmin2
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...-
Channel: Articles
07-20-2026, 11:48 AM -
-
by SEQadmin2
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...-
Channel: Articles
07-09-2026, 11:10 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, 08-03-2026, 10:13 AM
|
0 responses
15 views
0 reactions
|
Last Post
by SEQadmin2
08-03-2026, 10:13 AM
|
||
|
Started by SEQadmin2, 07-31-2026, 02:55 AM
|
0 responses
32 views
0 reactions
|
Last Post
by SEQadmin2
07-31-2026, 02:55 AM
|
||
|
Started by SEQadmin2, 07-24-2026, 12:17 PM
|
0 responses
23 views
0 reactions
|
Last Post
by SEQadmin2
07-24-2026, 12:17 PM
|
||
|
Started by SEQadmin2, 07-23-2026, 11:41 AM
|
0 responses
21 views
0 reactions
|
Last Post
by SEQadmin2
07-23-2026, 11:41 AM
|
Comment